Search

everythinglearnresearchcommunity

for

Search:↓

Intralesional triamcinolone acetonide is the most effective treatment for localized alopecia areata.

Tofacitinib shows promise for treating severe alopecia areata with good safety and effectiveness.

Combining Ayurvedic therapies with minoxidil is more effective for hair growth in men than using minoxidil alone.

JAK inhibitors are more effective and safer for treating alopecia areata than dupilumab and apremilast.

Tofacitinib and methotrexate successfully treated a woman's severe skin, joint, and hair loss issues.

A woman's eyelashes grew thicker and longer after taking topiramate, but returned to normal when she stopped the medication.

The herbal combination of saw palmetto and stinging nettle reduces nighttime urination in men with urinary issues.

A new mix of anthralin and calcipotriene might help treat severe hair loss.

Agomelatine might help stop hair loss caused by valproate.

Tofacitinib effectively reduced hair loss in alopecia areata patients without adverse effects.

Tofacitinib helps hair regrowth in alopecia areata but relapse is common after stopping treatment.

Amitriptyline can cause temporary hair loss, which stops after discontinuing the drug.

Intralesional triamcinolone acetonide via Dermojet is highly effective for treating alopecia areata.

Imipramine and pseudoephedrine treatment can effectively restore normal ejaculation in patients with diabetes, increasing their chances for pregnancy.

Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.

Entadfi, a mix of finasteride and tadalafil, is used for BPH.

Co-trimoxazole may help treat autoimmune diseases.

Intralesional triamcinolone injections can effectively stop frontal fibrosing alopecia with minimal side effects.

A woman experienced excessive hair growth after using a hair loss treatment with minoxidil.

Bexarotene gel shows promise as a new treatment for alopecia areata.

Targeting NMMHC IIA may help treat blood-brain barrier damage.

Most patients successfully switched from the original adalimumab to a biosimilar with few reverting due to reduced effectiveness or side effects.